Serum lipid ratios as novel prognostic biomarkers for patients with locally advanced breast cancer treated with neoadjuvant therapy
- 24 June 2024
- journal article
- research article
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 136 (5) , 541-550
Abstract
Objectives To investigate the association between lipid ratios and survival outcomes in patients with locally advanced breast cancer (LABC) undergoing neoadjuvant chemotherapy. Method This retrospective study included patients with LABC receiving neoadjuvant chemotherapy. Serum lipid levels were prospectively measured at baseline. Associations of triglyceride to total cholesterol (TG/TC), triglyceride to high-density lipoprotein (TG/HDL) and triglyceride to low-density lipoprotein (TG/LDL) ratios with prognosis were evaluated. Results Patients with high TG/TC (adjusted hazard ratio [aHR] = 2.47, 95% CI: 1.10, 5.56, p = 0.029), TG/HDL (aHR = 2.73, 95% CI: 1.16, 6.41, p = 0.021) and TG/LDL (aHR = 2.50, 95% CI: 1.11, 5.65, p = 0.027) ratios were more likely to experience disease-free survival (DFS) events. Subgroup analysis suggested that the prognostic impact of lipid ratios was more pronounced in patients with negative HER2 status or those at a high risk of recurrence (e.g. clinical stage III, Ki67 > 30%). Additionally, higher lipid ratios tended to indicate early DFS events (0 similar to 2 years) (TG/TC p = 0.021, TG/HDL p = 0.046, TG/LDL p < 0.001), and the TG/LDL ratio demonstrated the best predictive efficacy (TG/TC vs. TG/HDL vs. TG/LDL, 1-year AUC: 0.724 vs. 0.676 vs. 0.846, 2-year AUC: 0.653 vs. 0.638 vs. 0.708). Conclusion Baseline serum TG/TC, TG/HDL and TG/LDL ratios were independent prognostic factors in patients with LABC undergoing neoadjuvant therapy. However, their utility in predicting the early DFS events warrants further investigation. Clinical trial registrationNCT05621564.Keywords
Funding Information
- National Natural Science Foundation of China
- Science and Technology Commission of Shanghai Municipality (No. 20DZ2201600)
- Shanghai Municipal Key Clinical Specialty
- Shanghai Rising-Star Program (No. 22QC140020)
- Shanghai Municipal Health Commission Health Industry Clinical Research Special Project (No. 202340085)
- Nurturing Fund of Renji Hospital (No. PYIII20-09)
This publication has 43 references indexed in Scilit:
- PARP Inhibitors for Breast Cancer TreatmentJAMA Oncology, 2024
- Value of the triglyceride–glucose index and non-traditional blood lipid parameters in predicting metabolic syndrome in women with polycystic ovary syndromeHormones, 2023
- The role of lipids in cancer progression and metastasisCell Metabolism, 2022
- Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021Annals of Oncology, 2021
- Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic interventionAdvanced Drug Delivery Reviews, 2020
- Pretreatment triglycerides‐to‐high density lipoprotein cholesterol ratio in postmenopausal women with endometrial cancerThe Kaohsiung Journal of Medical Sciences, 2019
- Associations of lipid parameters with insulin resistance and diabetes: A population-based studyClinical Nutrition, 2018
- Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progressionCellular and Molecular Life Sciences, 2015
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Metabolic profile, physical activity, and mortality in breast cancer patientsBreast Cancer Research and Treatment, 2009